Inferior vena cava filters in patients with advanced-stage cancer  by Mansour, Asem et al.
136original research reportInferior vena cava ﬁlters in patients
with advanced-stage cancerHematol Oncol Stem Cell Ther 7(4) Fourth QuAsem Mansour a, Yousef Ismael b, Hikmat Abdel-Razeq b,*
a Department of Radiology, King Hussein Cancer Center, Amman, Jordan, b Department of Internal Medicine, King Hussein Cancer
Center, Amman, Jordan
* Corresponding author at: Department of Internal Medicine, Head, Section of Hematology and Medical Oncology, King Hussein Cancer
Center, Amman 11194, Jordan. Tel.: +962 6 5300460x1000; fax: +962 6 5353001. Æ habdelrazeq@khcc.jo Æ Received for publication
24 April 2014 Æ Accepted for publication 1 September 2014
Hematol Oncol Stem Cell Ther 2014; 7(4): 136–141
ª 2014 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. All rights reserved.
DOI: http://dx.doi.org/10.1016/j.hemonc.2014.09.005BACKGROUND: Cancer and its treatment are recognized risk factors for venous thromboembolism (VTE).
Inferior vena cava (IVC) filters are utilized to provide mechanical thromboprophylaxis to prevent pulmonary
embolism (PE) or to avoid bleeding from systemic anticoagulation.
PATIENTS AND METHODS: A retrospective analysis of 107 cancer patients who had IVC filters inserted and
followed up at our institution was performed. All patients had active cancer; a majority (> 90%) had
advanced-stage disease, whereas only five patients (5.8%) had stages I or II disease.
RESULTS: Eighty six patients (80.3%) had their IVC filter placed through a jugular approach. Filter insertion was
not without complications; recurrent deep vein thrombosis (DVT) was reported in 10 (9.3%), PE in three (2.8%)
and filter thrombosis in one patient. The value of IVC filter in patients with advanced stage disease was very
limited: among 59 patients with stage IV disease for whom survival data was available, the median survival
was only 1.31 months (0.92–2.20) with 23 patients (39.0%) surviving less than a month, and 40 (67.8%) surviv-
ing less than three months.
CONCLUSIONS: Systemic anticoagulation can be safely offered for the majority of cancer patients. When the
risk of bleeding or PE is high, IVC filters can be utilized. However, the placement of such filters should take into
consideration the stage of disease and life expectancy of such patients. Patients with advanced-stage disease
may gain little benefit from IVC filter insertion.
KEYWORDS: Inferior vena cava filter; Cancer; Anticoagulation; BleedingVenous thromboembolism (VTE), which rep-resents a spectrum of diseases including bothdeep vein thrombosis (DVT) and pulmon-
ary embolism (PE), occurs more frequently in cancer
patients. Cancer and its treatment are recognized risk
factors for VTE. Studies have reported a sixfold
increased risk of VTE in cancer patients compared
to those without.1 Active cancer accounts for almost
20% of all new VTE events occurring in the commu-
nity.2 The risk varies by cancer type, and is especially
high among patients with malignant brain tumors and
adenocarcinoma of the ovary, pancreas, colon, stom-
ach, lung, prostate, and kidney.3
Treatment of VTE typically includes initial
anticoagulation with unfractionated heparin (UFH),
a low molecular weight heparin (LMWH) or apentasaccharide such as fondaparinux,4 along with
vitamin K antagonists such as warfarin. Thrombolytic
agents may be used in severe cases.5 Occasionally,
speciﬁc clinical situations are encountered in which
the risk of PE is very high or systemic anticoagulation
might be associated with high risk of bleeding. In
these instances, IVC ﬁlters are utilized to provide
mechanical thromboprophylaxis to prevent PE, the
life-threatening complication of VTE. Such ﬁlters
are inserted using a relatively noninvasive technique
to maintain central ﬂow. Thanks to newer technology,
IVC ﬁlters are becoming a very attractive option and
can function with anticoagulation to optimize the
prophylaxis strategy. In this study, the beneﬁts and
complications associated with IVC ﬁlter placement in
cancer patients will be reviewed.arter 2014
Table 1. Patient characteristics.
Gender
Male 59 (55.1%)
Female 48 (44.9%)
Primary cancer
Gastrointestinal 32 (29.9%)
Brain 16 (15.0%)
Lung 13 (12.1%)
Gynecological 11 (10.3%)
Breast 6 (5.6%)
Bladder 6 (5.6%)
Sarcoma 5 (4.7%)
Lymphoma 5 (4.7%)
Others 13 (12.1%)
Stage*
I 2 (2.3%)
PLACEMENT OF IVC FILTERS IN CANCER PATIENTS original research reportMATERIALS AND METHODS
This study was performed at a stand-alone, Joint
Commission International (JCI)-accredited compre-
hensive cancer center. Hospital database was searched
for all patients discharged with IVC ﬁlter insertion.
Additionally, the radiology database was queried for
cancer patients undergoing IVC ﬁlter placement. To
further identify patients, medical records were then
reviewed for data collection and conﬁrmation of
diagnosis.
For each conﬁrmed case, clinical data including
primary cancer, stage of disease, anti-cancer therapy,
indications for ﬁlter placement, complications and
survival post ﬁlter placement, were recorded
(Table 1).
Statistical analysis
Descriptive statistical analysis was performed to pres-
ent patients’ demographic and clinical characteristics.
All statistical analyses were carried out using SAS
Software (version 9.1). A p-value of 0.05 was consid-
ered to be statistically signiﬁcant, and was measured
using Chi-square.II 3 (3.5%)
III 20 (23.3%)
IV 61 (70.9%)
Unstageable 21(19.6%)
Active treatment
Chemotherapy with or
without radiotherapy
45 (42.1%)
Hormonal therapy with
or without radiotherapy
3 (2.8%)
Radiotherapy only 7 (6.5%)
Surgery alone (or with
chemotherapy and/or
radiotherapy)
19 (17.8%)
Palliative/hospice care 33 (30.8%)
Type of VTE
PE 14 (13.1%)
DVT 76 (71.0%)
Both DVT and PE 17 (15.9%)
PE: pulmonary embolism, DVT: deep vein thrombosis.
* Percentages from total cancers that have TNM (Tumor, Node, Metastasis) stages (86
patients).RESULTS
From January 2004 through March 2011, we identi-
ﬁed 107 patients who had their IVC ﬁlter inserted
and followed up at our institution. The 107 patients
comprised 59 (55.1%) men and 48 (44.9%) women,
and the mean age (±SD) of the whole group was
50.8 (±14.2) years. All patients had active cancer;
the most common types were gastrointestinal (32
cases; 29.9%), brain (16 cases; 15.0%) lung (13 cases;
12.1%) and gynecological tumors (11 cases; 10.3%).
At the time of ﬁlter insertion, the majority of patients
had advanced-stage disease; out of 86 patients with
identiﬁable TNM (Tumor, Node, Metastasis) stage,
81 patients (94.2%) had locally-advanced stage III
or metastatic stage IV disease, whereas only ﬁve
patients (5.8%) had stages I or II disease (Table 1).
During the six weeks prior to IVC ﬁlter insertion,
74 patients (69.2%) were on active anticancer therapy;
45 (42.1%) were on chemotherapy and seven (6.5%)
on radiotherapy. Nineteen patients (17.8%) had surgi-
cal intervention for their cancer while only three
(2.8%) were on hormonal therapy. The remaining
33 patients (30.8%) were on hospice and palliative
care service, with 18 (16.8%) already as DNR (Do
not Resuscitate). Prior to IVC ﬁlter insertion, a diag-
nosis of DVT was made on 76 patients (71.0%);Hematol Oncol Stem Cell Ther 7(4) Fourth Quarter 2014 137
Table 2. Indications for IVC filter. The bold values are used as a major
title (total number) under which subgroups were details.
Failure of anticoagulation 18 (16.8%)
Contraindication to anticoagulate* 85 (79.4%)
Immediate post-operative VTE 3 (36%)
Recent/active bleeding 52 (61.2%)
Large CNS tumor 21 (24.7%)
Thrombocytopenia 14 (16.5%)
Other contraindications 5 (5.9%)
Other indications 4 (3.7%)
Large, free floating iliocaval-thrombus 2 (1.9%)
Poor compliance with anticoagulation 1 (0.9%)
Patient at risk of fall while on anticoagulation 1 (0.9%)
*Some patients have more than one contraindication.
Table 3. IVC filter: approach, complications, anticoagulation. The bold
values are used as a major title (total number) under which subgroups
were details.
Numbers (%)
Approach
Femoral 18 (16.8)
Jugular 86 (80.3)
Unknown 3 (2.8)
Complications following filter placement
Recurrent DVT 10 (9.3)
Recurrent PE 3 (2.8)
Filter thrombosis 1 (0.9)
Anticoagulation following IVC filter 42 (39.3)
Enoxaparin 19 (45.2)
Tinzaparin 17 (40.5)
Fondaparinux 2 (4.8)
Unfractionated heparin 2 (4.8)
Warfarin 2 (4.8)
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had both DVT and PE (Table 1).
Contraindication to anticoagulation was the main
indication for IVC ﬁlter placement reported in 85
patients (79.4%), while 18 (16.8%) had their ﬁlter
inserted due to failure of anticoagulation; (patients
either had DVT and/or PE while on therapeutic doses
of anticoagulation). Other indications included large,
free-ﬂoating iliocaval thrombus and poor compliance
with anticoagulation. Details are listed in Table 2.
Filters were placed utilizing the jugular approach
in 86 patients (80.3%) while 18 (16.8%) had their ﬁl-
ter placed through a femoral approach. Site of inser-
tion was not reported in three patients.
Complications following IVC ﬁlter placement
occurred in 14 patients (13.1%); the majority were
recurrent DVT in 10 patients (9.3%), PE in three
patients (2.8%), and ﬁlter thrombosis in one patient.
Following IVC ﬁlter insertion, 42 patients (39.3%)
were also anticoagulated; the majority (86%) with
LMWH (enoxaparin or tinzaparin), while UFH,
fondaparinux and warfarin were given to two patients
(Table 3). Twenty (47.6%) of the 42 anticoagulated
patients were considered, at the time of IVCﬁlter inser-
tion, as having a contraindication to anticoagulation.
Survival data following IVC ﬁlter insertion was
available for 100 patients. The median survival for
the whole group was 2.39 months (range: 0.03–
60.2). The median survival for patients with stage
III and IV disease were 7.97 (1.90–17.08) and
1.31 months (0.92–2.20), respectively (p = 0.0119);
(Fig. 1). Few patients had stage I and II disease(two had stage I while three others had stage II dis-
ease) and thus were excluded from survival analysis.
Among the 59 patients with stage IV disease for
whom survival data was available, 23 (39.0%) survived
less than a month, while 40 (67.8%) survived less than
three months. Survival of patients with stage III dis-
ease fared better, with only one out of 20 patients
(5.0%) surviving less than a month, while 14 patients
(70.0%) survived more than three months.DISCUSSION
Inferior vena cava ﬁlters are utilized in many clinical
situations.6,7 However, many such indications are
subjective and consensus might occasionally be difﬁ-
cult to reach. In a community-based study, research-
ers at McMaster University reviewed 1547 local
county residents with conﬁrmed diagnosis of acute
VTE and without a prior IVC ﬁlter. Following the
VTE, 203 patients (13.1%) had an IVC ﬁlter placed.
In reviewing the indications for IVC ﬁlter placement,
panel members unanimously agreed that the use of
IVC ﬁlter was appropriate in 51% of the cases and
inappropriate in 26%. No consensus was reached
among the remaining 23% of cases.8Hematol Oncol Stem Cell Ther 7(4) Fourth Quarter 2014
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Figure 1. Overall survival.
PLACEMENT OF IVC FILTERS IN CANCER PATIENTS original research reportThe clinical beneﬁt of IVC ﬁlter placement was
addressed in one prospective trail (the PREPIC study)
in which 400 patients with proximal DVT who were
at risk for PE, were randomized to receive IVC ﬁlter
(200 patients) or no ﬁlter (200 patients); both groups
were anticoagulated with LMWH or unfractionated
heparin. At day 12, two patients (1.1%) assigned to
receive ﬁlters, as compared with nine patients (4.8%)
assigned to receive no ﬁlters, had symptomatic or
asymptomatic PE (odds ratio, 0.22; 95% conﬁdence
interval, 0.05–0.90). However, at two years, 37
patients (20.8%) assigned to the ﬁlter group, as com-
pared with 21 patients (11.6%) assigned to the no-ﬁl-
ter group, had recurrent DVT (odds ratio, 1.87; 95%
CI, 1.10–3.20).9 This study was updated few years
later: patients with IVC ﬁlters experienced a greater
cumulative incidence of symptomatic DVT (35.7%
versus 27.5%; HR 1.52, CI 1.02–2.27; p = 0.042),
but signiﬁcantly fewer symptomatic PE (6.2% versus
15.1%; HR 0.37, CI 0.17–0.79; p = 0.008).10 The
conclusion from this long-term follow-up was similar
to the original report; that is, with an IVC ﬁlter there
is an equivalent trade-off of fewer PE at the cost of
more DVTs. There was no difference in long-term
morbidity or mortality between the two groups.
Given the lack of long-term beneﬁts of IVC ﬁlters;
temporary, retrievable ﬁlters have increasingly gained
interest. Various retrievable ﬁlters have recently
received approval for temporary insertion. Recent data
suggests that the use of these ﬁlters may be associated
with low rates of PE and insertion complications.11–13Hematol Oncol Stem Cell Ther 7(4) Fourth Quarter 2014Regardless of the type of ﬁlter placed, the most
recent American Colleague of Chest Physicians
(ACCP) guidelines recommend systemic anticoagula-
tion, when possible, even with the ﬁlter in place.14
This is evident in our study patients; almost 40% of
them were anticoagulated, half of them were initially
considered to have a contraindication to anticoagula-
tion and thus had the ﬁlter inserted.
Cancer itself, or its treatment, might result in
numerous clinical complications that make systemic
anticoagulation very risky. Venous thromboembolic
disease is a frequent complication in patients with
intracranial malignancies. Some primary brain
tumors like gliomas or secondary metastatic tumors
to the brain are either bulky or excessively vascular,
thus increasing the risk of bleeding with or without
systemic anticoagulation.15 Brain metastases from
melanoma, choriocarcinoma, thyroid, and renal cell
carcinoma have particularly high propensities for
spontaneous hemorrhage while metastatic tumors
from sites like lung and breast are less likely to bleed
spontaneously.16 However, not all patients with
intracranial malignancies are at higher risk of bleed-
ing with anticoagulation. Complication rates of
IVC ﬁlters in patients with brain tumors are higher
than commonly perceived and may outweigh the risk
of anticoagulation. Researchers at Brigham and
Women’s Hospital in Boston reviewed the records
of 49 patients with intracranial malignancies and
venous thromboembolic disease to determine the
effectiveness and complications resulting from139
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systemic anticoagulation or IVC ﬁlter placement. Of
the 42 patients who received IVC ﬁlters, a strikingly
high percentage (62%) developed one or more com-
plications; 12% developed recurrent PE, while 57%
developed ﬁlter thrombosis, recurrent DVT, or
post-phlebitic syndrome. These complications
severely reduced the quality of life of affected
patients. Only 15 (31%) patients were treated with
anticoagulation, seven of them because of continued
thromboembolic disease. None of these 15 patients
had proven hemorrhagic complications.17
Our data questions the value of inserting IVC ﬁl-
ter for patients with advanced stage cancer; 67% of
them survived less than three months post ﬁlter place-
ment. We are not alone in questioning the need to
insert IVC ﬁlters in cancer patients with advanced-
stage disease. Many recent studies have questioned
this practice particularly in cancer patients with
advanced-stage disease whose survival is short and
therefore prevention of PE might be of little clinical
beneﬁt and a poor utilization of resources. In a study
that included 116 cancer patients; 42 (46%) of the 91
patients (78%) with stage IV disease who had ﬁlter
inserted died of cancer within six weeks and only16
(14%) were alive at one year.18
The beneﬁts of IVC ﬁlter placement on overall
survival were addressed in a recent retrospective
study that examined 206 consecutive cancer patients
with VTE. Patients were classiﬁed into three treat-
ment groups: anticoagulation-only (n = 62), IVC ﬁl-
ter-only (n = 77), or combination of both IVC ﬁlter
and anticoagulation (n = 67). Median overall survival
was signiﬁcantly greater in patients treated with anti-
coagulation (13 months) compared to those treated
with IVC ﬁlters (two months) or combination of
both (3.25 months; P < 0.0002). IVC ﬁlter patients
were 1.9 times more at risk of death than anticoag-
ulation only (hazard ratio = 0.528; 95% conﬁdence
interval = 0.374–.745). Multivariate analysis revealed
that performance status and type of thrombus were
not confounders and had no effect on overall sur-
vival.19 However, mortality can be related to the
severity of the underlying condition(s) of these
patients rather than to the complications of the
IVC ﬁlter itself.In another study, the survival beneﬁt of placing
IVC ﬁlters in patients with late-stage malignancy
was evaluated in a group of 5970 cancer patients at
a tertiary care facility. Retrospective analysis identiﬁed
55 consecutive patients with stage III or IV malignant
disease and VTE who received IVC ﬁlters. In a case
control study, 16 patients with VTE but without
IVC ﬁlter were matched for age, sex, type of malig-
nancy, and stage of disease. Filter placement prevented
PE in 52 patients (94.5%); however, four patients
(7.3%) had complications related to the procedure;
13 patients (23.6%) with late-stage cancer survived
less than 30 days following placement of the ﬁlter;
another 13 patients (23.6%) in this group, however,
survived more than one year. The authors concluded
that IVC ﬁlter placement conferred no survival bene-
ﬁt compared to the control group and that the survival
of patients with advanced-stage cancer was limited
primarily by the malignant process.20 However, in a
study that included 308 cancer patients with VTE
and IVC ﬁlters, researchers at M.D. Anderson Can-
cer center concluded that such ﬁlters are safe and
effective in preventing PE-related deaths in selected
cancer patients. However, patients with a history of
DVT and bleeding or advanced disease had the lowest
survival after IVC ﬁlter placement.21CONCLUSIONS
Venous thromboembolism is commonly encountered
in cancer patients. While systemic anticoagulation can
be safely offered for the majority of such patients,
the risk of bleeding or PE can occasionally be high.
Placement of IVC ﬁlters in cancer patients should
take into consideration disease stage and life expec-
tancy. While such ﬁlters can be effective in preventing
PE, there may be limited survival beneﬁt in patients
with advanced-stage malignancies. Many studies have
suggested that placement of IVC ﬁlters in such
patients does not improve survival and may negatively
affect quality of life.CONFLICT OF INTEREST DISCLOSURE
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